Broad-spectrum peptide antigen of the novel coronavirus SARS-COV-2, specific neutralizing antibody and use thereof

Abstract

The present disclosure provides a broad-spectrum peptide antigen of SARS-COV-2, a specific neutralizing antibody and use thereof. A broad-spectrum peptide antigen of SARS-COV-2, with an amino acid sequence comprising SEQ ID NO: 1, reacts with human SARS-COV-2 positive serum, and can specifically bind to a novel coronavirus antibody. Based on the peptide sequence of the present disclosure, a fusion protein with broad-spectrum triple tandem peptides of SARS-COV-2 is prepared using PCR, prokaryotic expression, and protein purification technology which simulates the trimeric mode of SARS-COV-2 S protein in its natural state. The fusion protein is used as an antigen to immunize mice, and can produce a specific anti-SARS-CoV-2 neutralizing antibody. The neutralizing antibody may be promising in anti-infective treatment, vaccine development and detection kit development for SARS-COV-2.

Dependencies are inferred from the claim text.